5clm

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
'''Unreleased structure'''
+
==1,4-Oxazine BACE1 inhibitors==
 +
<StructureSection load='5clm' size='340' side='right' caption='[[5clm]], [[Resolution|resolution]] 2.61&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[5clm]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5CLM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5CLM FirstGlance]. <br>
 +
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=52K:N-{3-[(3R)-5-AMINO-3-METHYL-3,6-DIHYDRO-2H-1,4-OXAZIN-3-YL]PHENYL}-5-CHLOROPYRIDINE-2-CARBOXAMIDE'>52K</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene></td></tr>
 +
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Memapsin_2 Memapsin 2], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.46 3.4.23.46] </span></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5clm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5clm OCA], [http://pdbe.org/5clm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5clm RCSB], [http://www.ebi.ac.uk/pdbsum/5clm PDBsum]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/BACE1_HUMAN BACE1_HUMAN]] Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.<ref>PMID:10677483</ref> <ref>PMID:20354142</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
1,4-Oxazines are presented, which show good in vitro inhibition in enzymatic and cellular BACE1 assays. We describe lead optimization focused on reducing the amidine pKa whilst optimizing interactions in the BACE1 active site. Our strategy permitted modulation of properties such as permeation and especially P-glycoprotein efflux. This led to compounds which were orally bioavailable, centrally active and which demonstrated robust lowering of Abeta levels in vivo in mouse and dog models. The amyloid lowering potential of these molecules makes them valuable leads in the search for new BACE inhibitors for the treatment of Alzheimer's Disease.
-
The entry 5clm is ON HOLD until Paper Publication
+
1,4-Oxazine beta-secretase (BACE1) inhibitors: from hit generation to orally bioavailable brain penetrant leads.,Rombouts FJ, Tresadern G, Delgado O, Martinez Lamenca C, Van Gool M, Garcia-Molina A, Alonso De Diego SA, Oehlrich D, Prokopcova H, Alonso JM, Austin N, Borghys H, Van Brandt S, Surkyn M, De Cleyn M, Vos A, Alexander R, Macdonald GJ, Moechars D, Gijsen HJ, Trabanco AA J Med Chem. 2015 Sep 17. PMID:26378740<ref>PMID:26378740</ref>
-
Authors: Rombouts, F., Tresadern, G., Delgado, O., Martinez Lamenca, C., Van Gool, M., Garcia-Molina, A., Alonso De Diego, S., Oehlrich, D., Prokopcova, H., Alonso, J.M., Austin, N., Borghys, H., Van Brandt, S., Surkyn, M., De Cleyn, M., Vos, A., Alexander, R., MacDonald, G., Moechars, D., Trabanco, A., Gijsen, H.
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
 
+
</div>
-
Description: 1,4-Oxazine BACE1 inhibitors
+
<div class="pdbe-citations 5clm" style="background-color:#fffaf0;"></div>
-
[[Category: Unreleased Structures]]
+
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Memapsin 2]]
 +
[[Category: Alexander, R]]
 +
[[Category: Alonso, J M]]
 +
[[Category: Austin, N]]
 +
[[Category: Borghys, H]]
 +
[[Category: Brandt, S Van]]
 +
[[Category: Cleyn, M De]]
 +
[[Category: Delgado, O]]
 +
[[Category: Diego, S Alonso De]]
 +
[[Category: Garcia-Molina, A]]
 +
[[Category: Gijsen, H]]
 +
[[Category: Gool, M Van]]
 +
[[Category: Lamenca, C Martinez]]
 +
[[Category: MacDonald, G]]
 +
[[Category: Moechars, D]]
[[Category: Oehlrich, D]]
[[Category: Oehlrich, D]]
-
[[Category: Tresadern, G]]
 
-
[[Category: Moechars, D]]
 
-
[[Category: Delgado, O]]
 
-
[[Category: Alexander, R]]
 
-
[[Category: De Cleyn, M]]
 
-
[[Category: Surkyn, M]]
 
[[Category: Prokopcova, H]]
[[Category: Prokopcova, H]]
-
[[Category: Garcia-Molina, A]]
 
-
[[Category: Van Gool, M]]
 
-
[[Category: Martinez Lamenca, C]]
 
[[Category: Rombouts, F]]
[[Category: Rombouts, F]]
-
[[Category: Alonso, J.M]]
+
[[Category: Surkyn, M]]
-
[[Category: Austin, N]]
+
-
[[Category: Alonso De Diego, S]]
+
[[Category: Trabanco, A]]
[[Category: Trabanco, A]]
-
[[Category: Borghys, H]]
+
[[Category: Tresadern, G]]
-
[[Category: Van Brandt, S]]
+
-
[[Category: Gijsen, H]]
+
[[Category: Vos, A]]
[[Category: Vos, A]]
-
[[Category: Macdonald, G]]
+
[[Category: Bace1 protease inhibitor]]
 +
[[Category: Brain penetrant]]
 +
[[Category: Hydrolase]]
 +
[[Category: Orally bioavailable]]
 +
[[Category: Proteros biostructures gmbh]]

Revision as of 14:33, 30 September 2015

1,4-Oxazine BACE1 inhibitors

5clm, resolution 2.61Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools